Horizon Pharma (HZNP) Receives USPTO Notice of Allowance for RAYOS-Related Patent

August 18, 2016 8:30 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Horizon Pharma (Nasdaq: HZNP) announced that the United States Patent and Trademark Office (USPTO) has granted a Notice of Allowance for U.S. patent application number 14/563,000 (U.S. publication number 2015-0141388), entitled "Delayed-Release Glucocorticoid Treatment of Rheumatoid Disease" that covers Horizon’s U.S. approved medicine RAYOS (prednisone) delayed-release tablets.

The Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire August 3, 2027. After issuance, Horizon plans to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. This will be the eighth U.S. patent to be listed in the Orange Book for RAYOS.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation

Add Your Comment